Ϫ0.02, pϭ0.042), low vision in both eyes (difference: Ϫ0.02, pϭ0.041), and blindness in both eyes (difference: Ϫ0.10, pϽ0.0001) had lower EQ-5D score than those without visual impairment. Singapore Indians with low vision in both eyes (difference: Ϫ0.03, pϭ0.0081), low vision in one eye and blindness in the other eye (difference: Ϫ0.09, pϽ0.0001), and blindness in both eyes (difference: Ϫ0.16, pϭ0.0004) had lower EQ-5D score than those without visual impairment. After adjusted for age, gender and co-morbidities, none of the 5 eye conditions was associated with reduction in EQ-5D scores in Malays or Indians, except that Indians with cataract had lower EQ-5D scores than those without cataract (difference: Ϫ0.02, pϭ0.0431). CONCLUSIONS: Health burden is associated with visual impairment, but not with the presence of the eye conditions. Vision problems pose more health burden to Indians than Malays in Singapore.
OBJECTIVES:
To evaluate the effect of aqueous extract of Boswellia serrata Roxb oleo gum on urinary electrolytes, pH and diuresis in normal albino rats. METHODS: Oleo gum weighing 500g was soaked in hot boiling water (1L) at room temperature for 3 days with occasional shaking. Filtrate was evaporated on rotary evaporator under reduced pressure (Ϫ760 mmHg) to a thick, semi-solid pasty mass of dark drown color that was completely solubilized in both distilled water and normal saline for in-vitro and in-vivo experimentation. Phytochemical analysis was carried out for alkaloids, saponins, anthraquinones, flavanoids and tannins. For invivo activity, five groups of with six animals in each were administered normal saline (10 ml/Kg, i.p.), Furosemide (10mg/kg) and crude extracts of Boswellia sarrata (10, 30 and 50mg/kg of body weight), respectively. Toxicological effect of plant was undertaken in rats at a dose of 3000mg/kg. Data was expressed as mean Ϯ SEM and analyzed using Graph Pad Prism (Graph PAD, San Diego, USA). Student t-test was applied for data analysis. p values Ͻ0.05 were considered significant. RESULTS: Phytochemical screening of Boswellia serrata Roxb confirmed the presence of saponins and flavonoids. Furosemide induced significant diuresis and electrolytes (Na ϩ & K ϩ ) excretion while plant extracts increased urinary output and electrolytes excretion in a dose-dependent manner. Diuretic index of test groups were1.36, 2.06 and 2.9, respectively while, Lipschitz value also confirmed diuretic activity in dose dependent manner. Urinary pH remained unchanged during the course of the study whereas, no lethality was observed at the dose of 3000mg/kg. CONCLUSIONS: Aqueous Boswellia serrata oleo gum extracts administered particularly at the dose of 50mg/kg significantly induced water and electrolytes with no signs of toxicity.
URINARY/KIDNEY DISORDERS -Cost Studies

PUK2 ECONOMIC BURDEN OF HEMODIALYSIS AND PERITONEAL DIALYSIS IN A TERTIARY HOSPITAL IN CHINA
Zhang X 1 , Xuan X 2 , Wan Y 3 , Ye L 4 , Gao X 3 1 Shenzhen People 's Hospital, Shenzhen, Guangdong, China, 2 No. 2 Hospital of Xiamen, Xiamen, Fujian, China, 3 Pharmerit, Bethesda, MD, USA, 4 School of Public Health, Fudan University, Shanghai, Shanghai, China OBJECTIVES: To assess economic burden associated with hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) among patients with end-stage renal disease (ESRD) and treated in a tertiary hospital in China. METHODS: From Sept 2004 to Jan 2005, adult patients on HD or CAPD for at least 6 months were recruited. Resource utilization and costs were collected by medical records review and patient survey. The economic burden was divided into direct costs including medical (dialysis, drugs, lab, and inpatient) and nonmedical (transportation, hired caregivers, and special nutritional products) and indirect costs due to productivity loss (human capital approach). The annualized costs expressed in 2010 Yuan(¥) were analyzed using Wilcoxon test and General Linear Model with gamma distribution and log link. RESULTS: Eighty-six patients [50 on CAPD and 36 on standard HD (3x4-hour weekly)] were included for the analysis, with 55% male and a mean age of 57.7Ϯ15.6 years. No differences were found in age, sex, education, payment method, income, originating disease, haemoglobin level, and dialysis time between HD and CAPD. Mean(SD)/Median of annual medical expenses were ¥91,476(42,935)/¥82,478 for HD and ¥68,898(11,698)/¥68,191 for CAPD (pϽ0.0001); nonmedical direct expenses were ¥5,883(4,256)/¥4,780 for HD and ¥3,041(3,835)/ ¥1,300 for CAPD (pϽ0.0001). No difference was found in indirect costs [¥3,167 (6,992) for HD and ¥5,064 (8,354) for CAPD (pϭ0.3)]. Total annual costs were ¥100,403(44,419)/¥90,262 for HD and ¥79,859(22,210)/¥77,681 for CAPD (pϭ0.001). Controlling for key factors/covariates, HD patients incurred 16% higher total cost compared to CAPD patients (pϭ0.01). Patients with younger age (pϭ0.005), public health insurance (pϽ0.0001), or originating disease of diabetes (pϭ0.03) incurred higher total costs compared to their counterparts, respectively. CONCLUSIONS: Patients received HD incurred more direct costs compared to patients undergoing CAPD. The findings of this study may help understand the disease burden and establish cost-effective treatment modalities in ESRD from Chinese societal perspective. 
PUK3 EVALUATION ON HEALTH EXPENDITURE AMONG PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY AFTER SPINAL CORD INJURY
OBJECTIVES:
To evaluate the annual health expenditure (AHE) in patients with neurogenic detrusor overactivity (NDO) after spinal cord injury (SCI). METHODS: Data containing 2 million randomly sampled individuals from the National Health Insurance Research Database (NHIRD) in Taiwan were used. Patients with emergency department visits or hospitalizations for SCI defined by ICD-9 codes 806.X and 952.X between 2006 and 2008 were retrieved. NDO was defined by: 1) diagnosis defined by ICD-9 codes 596.5 and 788.3 (excluding 596.53, paralysis of bladder); 2) pharmacological treatment for neurogenic voiding dysfunction and urinary symptoms such as alpha blockers, antimuscarinic agents, and cholinergic agents; and 3) procedures such as indwelling or intermittent catheterization defined by NHI codes 47,013C and 47,014C. All patients were followed for one year. The total AHE, as well as three subcategories, hospital, outpatient, and pharmacological treatment related cost were calculated respectively. Covariates including patient's demographics, hospital length of stay, concomitant medications, and comorbid conditions were considered in the final linear regression to compare the AHE between NDO and non-NDO group. RESULTS: A total of 941 eligible individuals with SCI were identified from 2006 to 2008, of whom 165 (17.5%) were NDO cases with a mean age of 54 and consisting of 64% male. The total AHE was 494,325 (Ϯ499,259) and 108,529 (Ϯ147,287) N.T. dollars in NDO and non-NDO group, respectively. After adjusting by regression model, the total AHE was higher in NDO (␤ϭ364,611; SEϭ21,082; pϽ0.001) than non-NDO group. Higher AHE was also shown in NDO in each subcategory when comparing with non-NDO. CONCLUSIONS: A significant impact on the financial burden of NDO was shown in this study. Higher AHE associated with NDO may also reflective of the higher severity of SCI or other comorbid conditions.
PUK4 TOTAL ECONOMIC BURDEN OF BOTH PERITONEAL DIALYSIS AND RENAL ANEMIA TREATMENT
Mao WH 1 , Chen W 2 , Yu XQ 3 1 Center for Pharmacoeconomic Research and Evaluation, School of Public Health, Fudan University, Shanghai, China, 2 Fudan University, Shanghai, Shanghai, China, 3 The First Affiliated Hospital, Guangzhou, Guangdong, China OBJECTIVES: To estimate the total economic burden of both peritoneal dialysis and renal anemia treatment in China. METHODS: Eight medical centers with regular follow-up system for peritoneal dialysis patients in 6 provinces were selected for prospective observation research. Inclusion and exclusion criteria were set down before the study through the discussion with clinical experts. Patients had been recruited in the study since July of 2011. Patient baseline characteristics, treatment and expenditure for both outpatient and inpatient during 3-months follow-up duration were recorded. Direct medical costs included fee for registration and services, medical examination, drugs and medical consumable materials. Direct nonmedical costs included transportation fee and nursing fee. Off-work days were collected to estimate indirect costs. RESULTS: A total of 149 patients with records of 703 outpatient visits and 19 inpatient stays were collected. Mean age of patients is 50.9 with averagely 3.47 years of peritoneal dialysis treatment and 3.35 years of EPO treatment. The average frequency was 1.41 visits in medical centers per month and 1.23 visits in community health centers. The average cost of EPO was CNY1,518 (US$241) per month with average dosage of 16443IU. Total economic burden per peritoneal dialysis patient was CNY9,756 (US$1,549) per month, including CNY9,163 (US$1,454) for direct medical costs, CNY210 (US$33) for direct non-medical costs and CNY383 (US$61) for indirect costs. The share of total economic burden related to GDP per capita ranged from 1.3 times to 6.4 times in 6 sampling provinces. CONCLUSIONS: The total economic burden of both peritoneal dialysis and renal anemia treatment seems relatively high, which needs more attention from the government and society.
PUK5 CLINICAL AND ECONOMIC IMPACTS OF CLINICAL PHARMACY EDUCATION ON INFECTION MANAGEMENT AMONG PATENTS WITH CHRONIC KIDNEY DISEASE IN A HOSPITAL (INDONESIA)
Nasution A 1 , Syed Sulaiman SA 1 , Shafie AA 2 1 Universiti Sains Malaysia, Pulau Pinang, Malaysia, 2 Universiti Sains Malaysia, Penang, Malaysia OBJECTIVES: This study evaluated the clinical and economic impacts of clinical pharmacy education (CPE) on infection management among patients with chronic kidney disease (CKD) stage 4 and 5 in Haji Adam Malik (HAM) hospital, Indonesia. METHODS: A quasi-experimental economic evaluation comparing CPE impact on six-months CKD mortality was conducted based on payer perspective. The experimental group (nϭ63) received care by health care providers that were given CPE on DRPs and dose adjustment. The control group (nϭ80) was based on the historical cohort of patients that received care before the CPE. Measure of clinical outcome applied in this study was number of lives saved/100 patients treated. Cost-effectiveness (CE) ratios for stage 4 and 5 CKD patients without CPE and with CPE, incremental cost effectiveness ratios (ICERs) for stage 4 and 5 CKD patients were analyzed. RESULTS: Lives saved (%) in the treatment of CKD without CPE: CKD stage 4, 78.57; CKD stage 5, 57.58. Lives saved (%) in the treatment of CKD with CPE: CKD stage 4, 88.89; CKD stage 5, 65.45. Cost-effectiveness ratios for stage 4 without and with CPEs were Rp3,593,295.97 and Rp3,348,733.27, respectively. Cost-effec-A644 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 -A 6 8 1
